Showing Results for
- Academic Journals (35)
Search Results
- 35
Academic Journals
- 35
- Search Terms:
- 1From: Nature Reviews Drug Discovery. (Vol. 8, Issue 6) Peer-ReviewedCurrent pharmacotherapies for addiction represent opportunities for facilitating treatment and are forming a foundation for evaluating new medications. Furthermore, validated animal models of addiction and a surge in...
- 2From: Nature Reviews Drug Discovery. (Vol. 8, Issue 6) Peer-ReviewedAVOS Life Sciences has analysed the revenue contribution of organically developed, licensed or co-developed, acquired and joint venture products to the major Rx drug portfolios (MRDPs: the collection of branded drugs...
- 3From: Nature Reviews Drug Discovery. (Vol. 8, Issue 6) Peer-ReviewedQing, J. etal. J. Clin. Invest. 119, 1216-1229 (2009) Qing and colleagues developed an antibody, R3Mab, against fibroblast growth factor receptor 3 (FGFR3) that simultaneously blocked ligand binding, prevented receptor...
- 4From: Nature Reviews Drug Discovery. (Vol. 8, Issue 6) Peer-ReviewedOn 16 April 2009, GlaxoSmithKline (GSK) and Pfizer announced that they will create a company focused on the research, development and commercialization of new antiretroviral (ARV) medicines for HIV GSK will initially...
- 5From: Nature Reviews Drug Discovery. (Vol. 8, Issue 6) Peer-ReviewedThe formation of insoluble deposits of tangled proteins is a characteristic of several neurodegenerative diseases, including Alzheimer's disease, although its contribution to pathogenesis remains controversial. Serum...
- 6From: Nature Reviews Drug Discovery. (Vol. 8, Issue 6) Peer-ReviewedThe US Court of Appeals for the Federal Circuit (CAFC) has examined a case that looks at the importation of drugs--the marketing of which would be prohibited in the country of import because of other patented...
- 7From: Nature Reviews Drug Discovery. (Vol. 8, Issue 6) Peer-ReviewedCompetitive androgen receptor antagonists are used to treat prostate cancer but, even in the presence of such drugs, overexpression of androgen receptors can drive cellular proliferation, leading to a more aggressive...
- 8From: Nature Reviews Drug Discovery. (Vol. 8, Issue 6) Peer-ReviewedSanofi-Aventis has launched its 200 million € 'BIOLAUNCH' project to produce monoclonal antibodies from 2012. The lowdown: In February 2009, Chief Executive Officer Chris Viehbacher was reported to have said that...
- 9From: Nature Reviews Drug Discovery. (Vol. 8, Issue 6) Peer-ReviewedZhang, M.-Z. et al. J. Clin. Invest. 119, 876-885 (2009) Cardiovascular risks associated with selective cyclooxygenase 2 (COX2) inhibitors limit their use in the prevention of colorectal cancer. Zhang and colleagues...
- 10From: Nature Reviews Drug Discovery. (Vol. 8, Issue 6) Peer-ReviewedA greater understanding of the mechanisms underlying the inflammatory response has identified numerous protein kinases that act as essential components in inflammatory signalling, and so could represent potential...
- 11From: Nature Reviews Drug Discovery. (Vol. 8, Issue 6) Peer-ReviewedRecent breakthroughs in the determination of the crystal structures of G protein-coupled receptors (GPCRs) have provided new opportunities for structure-based drug design strategies targeting this protein family. With...
- 12From: Nature Reviews Drug Discovery. (Vol. 8, Issue 6) Peer-ReviewedInflammation is an evolutionarily conserved host reaction that is initiated in response to trauma, tissue damage and infection. It leads to changes in tissue homeostasis and blood flow, immune-cell activation and...
- 13From: Nature Reviews Drug Discovery. (Vol. 8, Issue 6) Peer-ReviewedWilliam B. Mattes, Ph.D. Director of Toxicology, The Critical Path Institute, Tucson, Arizona and Rockville, Maryland, USA. The Critical Path (C-Path) Institute leads the Predictive Safety Testing Consortium (PSTC),...
- 14From: Nature Reviews Drug Discovery. (Vol. 8, Issue 6) Peer-ReviewedWhat do you consider have been the main reasons for mega-mergers of pharmaceutical companies in the past two decades? Primarily they have been driven by the short-term commercial need to maintain high profitability....
- 15From: Nature Reviews Drug Discovery. (Vol. 8, Issue 6) Peer-ReviewedTargeting the ubiquitin-proteasome system (UPS) has proved clinically useful in cancer, with the proteasome inhibitor bortezomib approved for the treatment of multiple myeloma and relapsed mantle cell lymphoma. Writing...
- 16From: Nature Reviews Drug Discovery. (Vol. 8, Issue 6) Peer-ReviewedThe recent swine-associated H1N1 flu pandemic emphasizes the need for new antiviral drugs, better vaccine manufacturing facilities and the use of new vaccine technology, such as adjuvants. The lowdown: The recent H1N1...
- 17From: Nature Reviews Drug Discovery. (Vol. 8, Issue 6) Peer-ReviewedChronic myelogenous leukaemia (CML) is a myeloproliferative disorder characterised by a chromosomal translocation that gives rise to the Philadelphia (Ph) chromosome, which encodes the fusion gene BCR-ABL. The product of...
- 18From: Nature Reviews Drug Discovery. (Vol. 8, Issue 6) Peer-ReviewedA recent analysis of the Pharmaprojects database revealed that between 2000 and 2008, 1,941 drugs were discontinued and, where companies disclosed a reason for the discontinuation, in a startling 52% of cases the reasons...
- 19From: Nature Reviews Drug Discovery. (Vol. 8, Issue 6) Peer-ReviewedNucleotide-binding and oligomerization domain (NOD)-like receptors (NLRs) are a family of intracellular sensors that have key roles in innate immunity and inflammation. Whereas some NLRs--including NOD1, NOD2, NAIP (NLR...
- 20From: Nature Reviews Drug Discovery. (Vol. 8, Issue 6) Peer-ReviewedMerck has signed an exclusive worldwide licensing agreement for an investigational human monoclonal antibody (mAb) combination, co-developed by Medarex and Massachusetts Biological Laboratories (MBL) of the University of...